Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Eiber

Showing results (101-110 of 377) with videos related to

Pageof 38
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 14, 2017
The Impact of Somatostatin Receptor-Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-AnalysisMartin Barrio, Johannes Czernin, Stefano Fanti, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 25, 2025
[<sup>18</sup>F]Flotufolastat PET/MRI in Patients with Suspected Prostate Cancer: Correlation with Histopathologic Biopsy ResultsNicola Gabler, Sonja Kirchhoff, Andreas Sauter, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|January 18, 2020
Deep Neural Network for Automatic Characterization of Lesions on 68Ga-PSMA PET/CT ImagesYu Zhao, Andrei Gafita, Giles Tetteh, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 14, 2021
Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using <sup>19</sup>F/<sup>177</sup>Lu-rhPSMA-7.3 and <sup>177</sup>Lu-PSMA I&TNahid Yusufi, Alexander Wurzer, Michael Herz, et al.
AJR. American Journal of Roentgenology|June 28, 2018
Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future ApplicationsThomas A Hope, Ali Afshar-Oromieh, Matthias Eiber, et al.
EJNMMI Research|October 14, 2024
Matched-pair analysis of mCRPC patients receiving <sup>177</sup>Lu-labeled PSMA-targeted radioligand therapy in a 4-week versus 6-week treatment intervalAmir Karimzadeh, Charlotte-Sophie Hecker, Matthias M Heck, et al.
EJNMMI Research|June 18, 2026
Impact of different PSMA PET-based eligibility criteria on outcome of [<sup>177</sup>Lu]Lu-PSMA radioligand therapy using [<sup>18</sup>F]rhPSMA-7/[<sup>18</sup>F]rhPSMA-7.3 (Flotufolastat)Sonia Grigorascu, Thomas Langbein, Isabel Rauscher, et al.
Aktuelle Urologie|May 17, 2017
[Significance and Value of PSMA Ligands in Prostate Cancer]Claudia Gasch, Stefan Körber, Christophe Kremer, et al.
EJNMMI Research|December 4, 2019
Evaluation of SUV normalized by lean body mass (SUL) in <sup>68</sup>Ga-PSMA11 PET/CT: a bi-centric analysisAndrei Gafita, Jeremie Calais, Charlott Franz, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 22, 2022
<sup>177</sup>Lu-PSMA-I&T for Treatment of Metastatic Castration-Resistant Prostate Cancer: Prognostic Value of Scintigraphic and Clinical BiomarkersAmir Karimzadeh, Matthias Heck, Robert Tauber, et al.
Pageof 38

Showing results (101-110 of 377) with videos related to

Sort By:
Pageof 38
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 14, 2017
The Impact of Somatostatin Receptor-Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-AnalysisMartin Barrio, Johannes Czernin, Stefano Fanti, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 25, 2025
[<sup>18</sup>F]Flotufolastat PET/MRI in Patients with Suspected Prostate Cancer: Correlation with Histopathologic Biopsy ResultsNicola Gabler, Sonja Kirchhoff, Andreas Sauter, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|January 18, 2020
Deep Neural Network for Automatic Characterization of Lesions on 68Ga-PSMA PET/CT ImagesYu Zhao, Andrei Gafita, Giles Tetteh, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 14, 2021
Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using <sup>19</sup>F/<sup>177</sup>Lu-rhPSMA-7.3 and <sup>177</sup>Lu-PSMA I&TNahid Yusufi, Alexander Wurzer, Michael Herz, et al.
AJR. American Journal of Roentgenology|June 28, 2018
Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future ApplicationsThomas A Hope, Ali Afshar-Oromieh, Matthias Eiber, et al.
EJNMMI Research|October 14, 2024
Matched-pair analysis of mCRPC patients receiving <sup>177</sup>Lu-labeled PSMA-targeted radioligand therapy in a 4-week versus 6-week treatment intervalAmir Karimzadeh, Charlotte-Sophie Hecker, Matthias M Heck, et al.
EJNMMI Research|June 18, 2026
Impact of different PSMA PET-based eligibility criteria on outcome of [<sup>177</sup>Lu]Lu-PSMA radioligand therapy using [<sup>18</sup>F]rhPSMA-7/[<sup>18</sup>F]rhPSMA-7.3 (Flotufolastat)Sonia Grigorascu, Thomas Langbein, Isabel Rauscher, et al.
Aktuelle Urologie|May 17, 2017
[Significance and Value of PSMA Ligands in Prostate Cancer]Claudia Gasch, Stefan Körber, Christophe Kremer, et al.
EJNMMI Research|December 4, 2019
Evaluation of SUV normalized by lean body mass (SUL) in <sup>68</sup>Ga-PSMA11 PET/CT: a bi-centric analysisAndrei Gafita, Jeremie Calais, Charlott Franz, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 22, 2022
<sup>177</sup>Lu-PSMA-I&T for Treatment of Metastatic Castration-Resistant Prostate Cancer: Prognostic Value of Scintigraphic and Clinical BiomarkersAmir Karimzadeh, Matthias Heck, Robert Tauber, et al.
Pageof 38